Important: Formulation and dosage details

Formulation:

Solution for injection, pre-filled syringe (Amgevita) 20mg/0·4mL, 40mg/0·8mL (Restricted: hospital use only)

Notes:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection, pre-filled pen (Amgevita) 40mg/0·8mL (Restricted: hospital use only)

Notes:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection, pre-filled syringe (Humira) 40mg/0·4mL (Restricted: hospital use only)

Dosage:

As per SMC1243/17: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. 

and

SMC1143/16: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy. 

Notes:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection, pre-filled pen (Humira) 40mg/0·4mL (Restricted: hospital use only)

Dosage:

As per SMC1243/17: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. 

and

SMC1143/16: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy. 

Notes:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled pen 150mg, 300mg 

Dosage:

As per SMC2592: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment. 

Notes:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled syringe 150mg, 300mg 

Dosage:

As per SMC2592: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment. 

Notes:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot